Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of B7H3 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell (CMD03) in Relapse and Refractory Pediatric Solid Tumors

NCT06612645 is registered in ClinicalTrials.gov with Chulalongkorn University as lead sponsor.

NCT NCT06612645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06612645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of B7H3 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell (CMD03) in Relapse and Refractory Pediatric Solid Tumors
Lead sponsor
Chulalongkorn University
Phase
Phase 1
Overall status
Recruiting
Start date
April 1, 2025
Completion date
December 1, 2028
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric cancers, solid tumor pediatric